OpenAI’s quarterly revenue tops $10 billion for the first time, signaling a turnaround

1–2 minutes

Revenue surge and profitability gains

According to Bloomberg, OpenAI’s latest quarterly sales exceeded $10 billion, a milestone that marks a rebound after a sluggish start to the year. This figure represents an almost 50 percent increase from the $6.7 billion reported in the second quarter. The growth rate also accelerated sharply, up from an estimated 18 percent rise between the first and second quarters.

The company’s adjusted operating margin improved from a negative 150 percent in the second quarter to a negative 109 percent in the third quarter, indicating a narrowing loss profile despite continued spending on model development and scaling.

Competitive landscape and enterprise focus

While OpenAI posted strong top‑line growth—18 percent on a $5.7 billion base—it still trails its rival Anthropic in the enterprise segment. Anthropic, the creator of Claude, reported third‑quarter revenue of $17 billion and an annual revenue run rate that surged by $10 billion in a single month to $81 billion as of the end of October. OpenAI’s annual run rate now stands at $50 billion, according to Bloomberg.

OpenAI claims more than a billion users, though analysts note that the majority are likely free or low‑cost subscribers. The firm has responded by tightening pricing, offering discounts, enhancing its models, and developing enterprise‑oriented products and AI agents designed to automate tasks.

Anthropic is preparing for an initial public offering that could value the company at $1.4 trillion. The two firms calculate annualized revenue differently: Anthropic includes sales generated by its cloud partners, whereas OpenAI reports only its share of partner transactions.

Broader market pressures

Both OpenAI and Anthropic compete not only with each other but also with large tech players such as Meta, Amazon, Microsoft, and Google, as well as a growing number of capable open‑source models, particularly those originating from Chinese labs.